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Abstract. Neurotrophins (NTs) modulate the growth of human 
malignancies, including lung cancers. Our prospective study 
evaluated the accuracy of pleural NTs [nerve growth factor, 
brain-derived neurotrophic factor (BDNF), neurotrophin 3 
(nT3) and 4 (nT4)] levels for differentiating benign from malig-
nant pleural exudates. Levels of NTs were measured by ELISA 
in 170 patients with non-neutrophilic (<50%) exudative benign 
or malignant pleurisies diagnosed by pleuroscopy. Fifty-nine 
benign (9 infections and 50 inflammatory diseases) and 111 
malignant (50 extrathoracic tumors, 51 lung cancers and 10 
mesotheliomas) pleural exudates were diagnosed by thoracos-
copy. Levels of BDNF were significantly higher in malignant 
than in benign effusions [17 pg/ml (0-367) vs. 8 pg/ml (0-51), 
p<0.05]. ROC analysis showed an area under the curve of 
0.609 (p=0.012; best threshold 44 pg/ml). Pleural BDNF levels 
were significantly higher in pleural metastasis of pulmonary 
tumors and in mesothelioma than in pleural benign effusions. 
Finally, a higher proportion of pleural nT3 was detected in 
squamous cell lung carcinoma in comparison to that in non-
squamous cell lung carcinoma (72.7 vs. 10%, p<0.0001). NTs 
and particularly BDNF may play a role in the pathogenesis of 
malignant pleural effusions.
Introduction
Pleural effusion is a common problem which manifests in a 
wide range of local and systemic potentially life-threatening 
diseases. Accurate diagnosis is difficult without resorting to 
invasive procedures. In particular, diagnosis of malignant 
pleural effusion presents a challenge since its differentiation 
from benign effusion is often difficult using currently avail-
able parameters derived from thoracosynthesis. Although 
essential for distinguishing between a transudate and exudate 
(1), biochemical, microbiological and cytological pleural 
fluid analyses have poor value for identifying the cause of a 
pleural lymphocytic exudate (2). The sensitivity of cytological 
examination of pleural fluid and blind needle biopsy, even 
when combined together, is generally less than 75% (3-7). 
Although there is a huge interest in biomarkers (cytokines, 
matrix metalloproteinases, growth factors and tumor markers) 
for the diagnosis of pleural effusions, their lack of sensitivity 
and specificity limits their use. Moreover, there is a lack of 
accepted and reliable diagnostic criteria particularly for malig-
nancy based on morphological imaging (CT and MR imaging) 
(8-10). The development of inflammation in the pleura results 
in an increased vascular permeability, and pleural liquid 
accumulation is the result of increased fluid production and/
or reduced lymph drainage. This pleural fluid is enriched in 
proteins, inflammatory cells and mediators (5,11). Cytokine-
producing cells and cytokines, such as the vascular endothelial 
growth factor (VEGF) which is able to increase angiogenesis 
and enhance the permeability of vascular endothelial cells 
(12,13), are thought to be important in malignant pleural fluid 
formation (14,15).
In malignant pleural effusion, neoplastic cells infiltrate the 
pleural layer and growth progressively in the pleural cavity.
Nerve growth factor (NGF), brain-derived neurotrophic 
factor (BDNF), neurotrophin 3 (nT3) and neurotrophin 4 (nT4) 
comprise the mammalian neurotrophins (NTs), a family of 
structurally related growth factors that play a crucial role in 
the survival, development, differentiation, neurite outgrowth 
and maintenance of a specific neuronal population in the 
nervous system (16,17). They belong to a class of growth 
factors, secreted proteins, which are capable of signaling 
particular cells to survive, differentiate or grow mediated by 
two classes of receptors, p75 and the ‘Trk’ family of tyrosine 
kinase receptors.
Although classically known for their effects on neurons, 
NTs are multifunctional growth factors and exert numerous 
effects including differentiation of B-lymphocytes (18), hista-
mine release from mast cells (19), formation of intramyocardial 
blood vessels (20) and growth of follicles in the ovaries (21) 
on non-neuronal cells, particularly in immunocompetent cells 
and lymphoid organs (22). Interest in the NTs system has 
grown particularly in regards to several lung diseases (23-26). 
Under normal conditions, Trk B (the physiological high-affinity 
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receptor for BDNF) has been found to be involved in the devel-
opment and maintenance of the normal structure of the lung 
(27,28). In addition, NTs play a role in the modulation of certain 
human malignancies (29,30), such as myeloma (31), fibrosar-
coma (32), hepatocellular (33) and pancreatic (34) carcinoma as 
well as lung cancer (35,36). More importantly, there is in vitro 
evidence that compounds blocking NT signaling, such as k252a, 
are able to block lung cancer cell progression (37). Yet, to date, 
the role of NTs in malignant pleural effusion (38) and in meso-
thelioma (39) has been poorly investigated.
In the present study, we aimed to ascertain whether deter-
mination of levels of four NTs (NGF, BDNF, nT3 and nT4) 
in pleural fluid aids in identifying the etiology of non-neutro-
philic pleural effusions and, in particular, in differentiating 
malignant from benign effusions.
Materials and methods
Patient selection. We conducted a prospective study, 
including 170 consecutive patients (mean age 66.4±13.4 years; 
range 18-96; 98 males and 72 females) who were treated at 
the Pneumology Department, CHU, Liège, between 2004 
and 2009. All patients presented with an exudative pleural 
effusion for whom the combination of chest X-ray, thoracic 
CT scanning (PQ 2000 4th generation; Picker, Cleveland, 
OH, USA) and thoracocentesis failed to provide an etiologic 
diagnosis. Therefore, the indication for thoracoscopy was 
justified along with pleural biopsy. In the chemical analysis, 
pleural effusion was considered to be an exudate according 
to Light's criteria (1). Thus, the pleural effusion had to meet at 
least one of the following criteria: ratio of pleural fluid protein 
to serum protein >0.5; ratio of pleural fluid lactic dehydroge-
nase (LDH) to serum lactic dehydrogenase >0.6; pleural fluid 
lactic dehydrogenase level greater than two-thirds of the upper 
limit of the serum normal value. Neutrophilic pleurisy (>50% 
neutrophils) (2) and empyema were excluded from this study. 
In our series thoracoscopy procedure allowed establishment of 
a diagnosis in each case.
Pleural fluid analysis. A diagnostic thoracocentesis of the 
pleural fluid (10 ml) was performed on each subject before thora-
coscopy was carried out. A first sample of 5 ml was subjected to 
routine biochemical analysis, including tests for pleural protein, 
glucose, LDH and amylase levels. A second sample of 5 ml was 
added to a tube containing ethylenediamino-tetraic-potassium 
anticoagulant for differential cell counting.
For NTs measurements, 20 ml of pleural fluid was centri-
fuged at 400 x g for 10 min at 4˚C. The supernatant was 
separated from the cell pellet. The supernatant was immedi-
ately stored at -70˚C until the ELISA was performed.
NTs (BDNF, NGF, nT3 and nT4) levels were determined 
according to the following commercially available enzyme-
linked immunosorbent assay (ELISA) kit (Duoset; R&D 
Systems Europe, Abingdon, UK). The ELISA was validated 
by determination of the assay sensitivity and spiking recovery. 
Assay sensitivity was determined by calculating the mean 
response of 10 sets of blanks and evaluating the mean plus 2 
standard deviations on the standard curve. The limit of detec-
tion was 5 pg/ml for BDNF, NGF and nT3 and 10 pg/ml for 
nT4. Spiking recovery was determined by adding 0, 7.5, 15.6, 
31.2, 62.5, 125, 250 and 500 pg/ml of NTs to a pool of 10 pleural 
liquids. The recovery for BDNF, NGF, nT3 and nT4, at a concen-
tration of 62.5 pg/ml, was 99, 61, >96 and 80%, respectively.
Table I. Demographic characteristics and etiologies of the 
patients with malignant or benign pleural effusions.
Benign pleural effusions
  Age (years) 68±13
  Gender (M/F) 38/21
  Etiology
    Infectious pleurisies (n=9)
      6 parapneumonic pleurisies
      3 tuberculosis
    Inflammatory pleurisies (n=50)
      1 Dressler's syndrome
      2 chronic pancreatitis
      3 heart failures
      1 post-radic
      6 benign asbestos
      1 uremic
      1 drug-induced
      1 post-traumatic
      3 connective tissue diseases
        2 rheumatoid arthritis
        1 scleroderma
      40 non-specific chronic inflammatory changes
Malignant pleural effusions
  Age (years) 65±14
  Gender (M/F) 61/50
  Etiology
    Pleural metastases of extrathoracic tumors (n=50)
      18 breast cancers
      5 ovarian cancers
      5 kidney cancers
      7 pancreatic cancers
      4 colic tumors
      2 rectal carcinomas
      2 prostatic carcinomas
      2 lymphomas
      1 skin cancer
      1 genital carcinoma
      1 acute leukemia
      1 laryngeal cancer
      1 unknown primary
    Pleural metastases of lung cancer (n=51)
      11 squamous non-small-cell carcinomas
      31 adenocarcinomas
      5 large-cell carcinomas
      2 sarcomas
      2 small-cell lung cancers
    Mesothelioma (n=10)
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Etiologic diagnosis of pleural exudate. The final diagnosis of 
the pleural effusion was obtained by invasive pleural biopsy 
during a thoracoscopy. When a diagnosis of benign disease 
was established, based on histopathology, the patients were 
followed up for at least 18 months to ensure absence of a 
malignant pleural process. Benign pleural effusions included 
both infectious (parapneumonic and tuberculosis) and inflam-
matory pleural effusions. Malignant pleural effusions were 
divided into three groups: i) pleural metastasis of an extra-
thoracic cancer, ii) pleural metastasis of a primary lung cancer 
and iii) mesothelioma.
The size of the pleural effusion was estimated in each 
patient by the total pleural fluid volume aspirated when starting 
the thoracoscopy procedure.
The protocol was approved by the local ethics committee, 
and informed consent was obtained from each subject prior to 
the study.
Statistical analysis. All data were expressed as the median 
(range) levels for pleural cell counts, pleural biochemical param-
eters and NTs. Characteristics of pleural fluid and pleural cell 
counts in malignant vs. benign pleural effusion were compared 
using the non-parametric Mann-Whitney test. A Kruskall-
Wallis analysis (Dunn's multiple comparisons post-test) was 
used to compare pleural neurotrophin levels in subgroups of 
malignant vs. benign pleural effusions. To calculate correlations 
between variables, the Spearman rank coefficient of correla-
tion was used. The accuracy of each pleural NT to distinguish 
malignant from benign pleural lesions was calculated with 
receiver operating characteristic (ROC) analyses. A p-value 
<0.05 was considered statistically significant.
Results
Clinical diagnosis. Thoracoscopic biopsies indicated benign 
pleural lesions in 59 patients and malignant pleural effusions 
in 111. Demographic characteristics and pleural effusion etiol-
ogies are provided in Table I. The gender ratio was different 
with females accounting for 45% of the malignant group, while 
only representing 36% of the benign group (NS).
Pleural cell counts and biochemical parameters. Biochemical 
and cytological characteristics of the pleural effusions are 
provided in Table II. There was no significant difference in 
pleural protein, LDH, glucose and amylase level and in protein 
Light's ratio between the malignant and benign pleural effu-
sions. However, LDH Light's ratio was significantly higher 
in the malignant effusions (p<0.05) (Table II). There was no 
significant difference in pleural cell counts between the benign 
and malignant effusions (Table II).
None of the pleural samples showed a positive bacterial 
growth during the culture, even when the pleural effusion was 
deemed to be of infectious origin.
Determination of neurotrophins in pleural effusions. The 
median level of pleural BDNF was 17 pg/ml (0-367) in patients 
with malignant pleural effusions, which was significantly 
higher compared to the value of 8 pg/ml (0-51) found in benign 
effusions (p<0.05) (Table III). By contrast, no significant 
difference was found in NGF and nT3 pleural levels between 
malignant and benign effusions (Table III). nT3 was only 
observed in 13.5% of the 170 pleural effusions, including 8 and 
16% of benign and malignant effusions, respectively (NS). nT4 
was undetectable with the exception of 1 patient with pleural 
metastasis of squamous lung carcinoma.
Pleural BDNF levels were positively correlated with pleural 
red cell counts (r=0.29, p<0.001), pleural neutrophil counts 
(r=0.16, p<0.05) and with pleural effusion volume (r=0.19, 
p<0.05). BDNF was negatively correlated with pleural eosino-
phil counts (r=-0.22, p<0.05) and pleural glucose (r=-0.22, 
p<0.01). No correlation was found with total pleural protein 
levels (r=-0.10, p>0.05).
ROC curve of BDNF for distinguishing between malig-
nant and benign effusions is presented in Fig. 1. Only the 
measurement of BDNF showed significant value in identifying 
malignant effusions with an area under the curve (AUC) of 
Table II. Pleural cell counts and biochemical parameters in the malignant and benign pleural effusions.
 Benign pleural effusions (n=59) Malignant pleural effusions (n=111)
RBC/mm3 2,515 (40-720,000) 4,640 (0-1,840,000)
WBC/mm3    710 (85-14,920)    600 (4-10,000)
Neutrophils (%)        6 (0-47)      11 (0-49)
Lymphocytes (%)      62 (3-98)      52 (0-100)
Reticulo/monocytes (%)      15 (0-83)      22 (0-94)
Eosinophils (%)        2 (0-73)        1 (0-43)
Proteins (g/l)       42 (20-62.9)   41.3 (10-68.3)
LDH (UI/l)    420 (286-1,735)    551 (120-6,512)
Amylase (UI/l)       39 (12-22,540)   37.5 (4-903)
Glucose (g/l)   0.90 (0.02-1.94)   0.84 (0.14-2.73)
Protein Pl/blood ratio   0.60 (0.28-0.88)   0.62 (0-1.16)
LDH Pl/blood ratio   0.94 (0.15-33)   1.40 (0-27)a
Values are expressed as median (range); ap<0.05.
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0.609 (p<0.05). Derived from this curve, the best cut-off point 
was found to be 44 pg/ml which gave a sensitivity, a specificity 
and an accuracy of 24, 99 and 50%, respectively. Sensitivities 
and specificities for different cut-off values for distinguishing 
benign from malignant pleurisies are presented in Table IV.
Regarding different subgroups of malignant and benign 
pleural effusions, a significant difference in pleural BDNF 
levels was noted, which was significantly higher in pleural 
metastasis of lung cancer and in mesothelioma when compared 
to benign effusions [19 pg/ml (0-232) and 27 pg/ml (0-367) 
vs. 8 pg/ml (0-51), respectively, p<0.05] (Fig. 2). ROC analysis 
showed BDNF may help to distinguish between pleural metas-
tasis of lung cancer and benign effusion (AUC=0.664, p<0.01; 
72 and 59% for sensitivity and specificity, respectively, for 
best threshold of 11 pg/ml), and between pleural metastasis 
of lung and extrathoracic cancers (AUC=0.613, p<0.05; 69 
and 56% for sensitivity and specificity, respectively, for best 
threshold of 12 pg/ml) (Table V). Finally, there was a strong 
trend for BDNF to identifying mesothelioma from benign 
effusion (AUC=0.703, p=0.055; 40 and 100% for sensitivity 
and specificity, respectively, for best threshold of 51 pg/ml). 
We found no significant difference in the four neurotrophin 
levels according to the etiology of the benign pleural effusions 
[infectious (n= 9) vs. inflammatory (n=50)].
In malignant pleural effusions, pleural nT3 concentrations 
were observed in 10% of pleural metastasis of extrathoracic 
cancer, in 10% of mesothelioma and in 23.5% of pleural 
metastasis of primary lung cancer (NS). In this last subgroup, 
a higher proportion of pleural nT3 was detected in squamous 
cell carcinoma in comparison to that in non-squamous cell 
carcinoma (72.7 vs. 10%, p<0.0001) (Fig. 3).
Discussion
The aim of the present study was to assess the levels of NTs in 
pleural effusion where etiology was not obvious. The present 
study demonstrated for the first time in a large and well-
characterized population of patients with non-neutrophilic 
exudates that, even though the pleural BDNF level was higher 
in malignant pleural effusions, it exhibited a rather limited 
clinical value in distinguishing between malignant and benign 
pleural effusions.
ROC curve analysis indicated that BDNF at a concentration 
of 44 pg/ml yields the best compromise between sensitivity 
and specificity, although we recognize it to be fairly modest 
as a diagnostic tool due to a low sensitivity (24%). However, 
this can be compared to what is usually found with chest CT 
scanner which has a sensitivity that may range from 22 to 35% 
according to the morphological chosen criteria (40), while 
specificity is around 80%.
Even though several NTs were reported to influence extra-
thoracic neoplastic cell differentiation and growth (29-32,41), 
in our study only BDNF levels were found to be significantly 
Table III. Comparison of pleural neurotrophin levels in benign 
and malignant pleural effusions.
Pleural Benign pleurisy Malignant pleurisy
neurotrophins (n=59) (n=111)
BDNF (pg/ml) 8 (0-51) 17 (0-367)a
NGF (pg/ml) 0 (0-120.3)   0 (0-376)
nT3 (pg/ml) 0 (0-43)   0 (0-137)
nT4 (pg/ml) 0 (0-0)   0 (0-28)
Values are expressed as median (range); ap<0.05.
Figure 1. Receiving operating characteristic (ROC) curves of BDNF for dif-
ferential diagnosis (malignant vs. benign) of the pleural effusions.
Table IV. Sensitivities, specificities, negative predictive value 
(NPV) and positive predictive value (PPV) for different cut-off 
values derived from ROC curves of BDNF for distinguishing 
benign from malignant pleurisies.
Cut-off Sensitivity Specificity NPV PPV
(pg/ml) (%) (%) (%) (%)
10 63 54 44 72
15 53 68 43 76
20 47 71 39 73
25 39 71 39 73
30 39 75 39 73
35 33 81 39 77
40 28 91 41 86
45 24 98 41 96
50 17 98 39 95
Figure 2. Comparison of pleural BDNF levels in different subgroups of 
pleurisy (benign effusion, pleural metastasis of extrathoracic tumor, pleural 
metastasis of lung cancer and mesothelioma). Dashed line represents the 
limit of the detection of our assay. Solid line represents the median value in 
the different pleurisies.
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increased in malignant effusions. Moreover, these increased 
levels were essentially due to lung cancer pleural metastasis and 
mesothelioma.
Our study confirms in a larger series of patients the results 
of Ricci et al who reported significantly higher concentrations 
of BDNF in malignant pleural effusions in comparison to 
inflammatory exudates and transudates (38).
The reason why BDNF is increased in malignant effusions 
is not clear. Although we cannot exclude that increased BDNF 
levels may partly be related to increased pleural endothelial 
permeability, the lack of correlation between pleural BDNF 
and protein levels suggests that there may be additional 
mechanisms involved. Local production of BDNF by meso-
thelial cells, recruited inflammatory and malignant cells is 
likely to contribute to the increased levels found in malignant 
effusions and points to the existence of an autocrine and/
or paracrine mechanism (35,36,38). Although we excluded 
pleural fluids with high neutrophil counts (>50%), we found a 
significant correlation between neutrophil counts and BDNF 
suggesting that recruited neutrophils may contribute together 
with tumoral cells to local BDNF production.
In contrast, the absence of a correlation between pleural 
LDH, a marker of tumor activity, and BDNF supports the 
hypothesis that pleural BDNF levels may not be directly related 
to tumor growth itself, but rather to an interaction between 
malignant cells and local mesenchymal or inflammatory cells. 
The significant relationship between the volume of pleural 
effusion and BDNF is in keeping with the role of this NT in 
controlling pleural fluid homeostasis (35,38). Implication of 
BDNF in vascular permeability regulation is further supported 
by the recognition of its involvement in cerebral edema and 
subsequent neuronal tissue damage (42).
Immunohistochemical analysis showed that Trk B recep-
tors, the BDNF receptors, were expressed in several neoplastic 
cells, fibroblasts and blood vessels (21,35). Activation of Trk B 
receptors may be a key mechanism in tumor cell survival 
after detachment from extracellular matrix (a process called 
‘anoikis’) (43). The particularly elevated levels of BDNF in 
malignant pleural fluid from lung cancer cells known to express 
high level of Trk B receptors (36) may cause a more aggressive 
pleural invasion as compared to extrathoracic tumors. Notably, 
an inverse relationship was found between pleural glucose and 
BDNF levels. This supports the idea that BDNF is increased 
when metabolic activity of the pleura is intense as in tumor cell 
proliferation (44,45). Additionally, a strong correlation was 
found between pleural red cell counts and BDNF levels which 
is in line with the role of BDNF in pleural neoangiogenesis, a 
phenomenon critical for tumor proliferation.
In contrast to BDNF, neither NGF nor nT3 were found to 
be significantly increased in pleural effusion of malignancies. 
Furthermore, nT3 pleural levels were only detected in 13.5% 
of all pleurisies, with a trend to a higher percentage of detec-
tion in malignant pleurisies (16%) vs. benign effusion (8%). 
Pleural nT3 level was observed in the majority of squamous 
cell lung carcinoma (73% of cases) which sharply contrasts 
to what was observed in other types of lung cancer histology 
(~10%). Our data corroborate those reported by Ricci et al for 
lung surgical samples (36).
NGF has been reported to be more commonly a regulator of 
differentiation and/or survival than a cancer cell growth factor 
(38). Down-regulation of NGF has even been demonstrated in 
aggressive human malignancies (46). In light of this view, we 
Table V. Receiving operating characteristics (ROC) curves of BDNF for distinguishing between the subgroups of pleural effusions.
 AUC p-value Cut-off (pg/ml) Sensitivity Specificity
Lung cancer pleural metastasis  0.664 0.002 11 72   59
vs. benign pleurisy
Lung cancer vs. extrathoracic  0.613 0.040 12 69   56
tumor pleural metastasis
Lung cancer pleural metastasis 0.516 0.590 57 40   88
vs. mesothelioma
Extrathoracic tumor pleural  0.534 0.550 43 18   97
metastasis vs. benign pleurisy
Extrathoracic tumor pleural 0.661 0.130 55 40   94
metastasis vs. mesothelioma
Mesothelioma vs. benign pleurisy 0.703 0.055 51 40 100
Figure 3. Comparison of pleural nT3 levels according to pleural metastasis of 
primary lung tumor histology (squamous cell carcinoma vs. non-squamous), 
pleural metastasis of extrathoracic tumor, mesothelioma and benign pleural 
effusions. Dashed line represents the limit of the detection of our assay. Solid 
line represents the median value in the different pleurisies.
DUYSINX et al:  NEUROTROPHIN IN PLEURAL MALIGNANCIES946
find no surprise that NGF levels were not increased in the malig-
nant pleural effusions.
In conclusion, albeit of a limited diagnosis value, our 
results demonstrated in a large patient series that malignant 
pleural effusions display increased BDNF levels which may 
contribute to the local growth and invasiveness of tumors. This 
may offer a novel target in the treatment strategy for malignant 
pleural diseases.
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